What to expect from targeted therapy for multiple myeloma

Targeted medicines act on features of myeloma cells or on processes that help those cells survive. Your haematology team may use one medicine or combine it with other treatments. The choice depends on disease activity, previous medicines, kidney function, blood counts, symptoms and whether a transplant pathway is being considered.

Some medicines are tablets, while others are injections or infusions. Treatment is often arranged in cycles, with rest periods or planned clinic visits. Blood and urine tests help assess abnormal protein, blood counts, kidney function and treatment effects; imaging or bone assessment may also be used when needed.

Take each dose exactly as prescribed and keep a written medicine schedule. Tell the team about numbness, constipation, diarrhoea, infections, swelling or new pain. Ask before starting supplements or non-prescription medicines, because interactions can alter treatment effects.

Your team may discuss infection prevention, hydration, bone protection and medicines to reduce treatment-related problems. Never change a dose or skip an appointment on your own; call the clinic if a dose is missed or vomiting prevents you from keeping medicine down.

Seek prompt advice for fever, chills, new cough, unusual bruising or bleeding, marked weakness, reduced urine, severe constipation, worsening numbness, or new severe back or limb pain. Emergency assessment is needed for sudden breathlessness, chest pain, confusion or inability to move a limb.

Ask what the medicine targets, why it suits your current treatment stage, how cycles are organised, which results show response, and what to do about a missed dose or new symptom.